Published in Am J Pathol on October 01, 2003
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
Pancreatic carcinogenesis. Pancreatology (2008) 2.60
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst (2012) 2.09
3D Chromosome Regulatory Landscape of Human Pluripotent Cells. Cell Stem Cell (2015) 1.81
Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol (2011) 1.65
Tumor suppressor functions of FBW7 in cancer development and progression. FEBS Lett (2012) 1.64
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
Maintenance of acinar cell organization is critical to preventing Kras-induced acinar-ductal metaplasia. Oncogene (2012) 1.48
BRAF and KRAS gene mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/IPMC) of the pancreas. Cancer Lett (2006) 1.46
Molecular signatures of pancreatic cancer. Arch Pathol Lab Med (2011) 1.46
Inactivation of Brca2 cooperates with Trp53(R172H) to induce invasive pancreatic ductal adenocarcinomas in mice: a mouse model of familial pancreatic cancer. Cancer Biol Ther (2011) 1.45
Genetic and epigenetic alterations in pancreatic carcinogenesis. Curr Genomics (2011) 1.33
The molecular and cellular heterogeneity of pancreatic ductal adenocarcinoma. Nat Rev Gastroenterol Hepatol (2011) 1.32
MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol (2012) 1.21
Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma. Mol Cancer (2014) 1.21
Fbxw7 regulates lipid metabolism and cell fate decisions in the mouse liver. J Clin Invest (2010) 1.17
FBXW7/hCDC4 controls glioma cell proliferation in vitro and is a prognostic marker for survival in glioblastoma patients. Cell Div (2007) 1.13
Molecular mechanism of pancreatic cancer--understanding proliferation, invasion, and metastasis. Langenbecks Arch Surg (2010) 1.10
Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma. Ann Surg (2006) 1.09
Molecular genetics of pancreatic ductal adenocarcinomas and recent implications for translational efforts. J Mol Diagn (2008) 1.04
Molecular analysis of PIK3CA, BRAF, and RAS oncogenes in periampullary and ampullary adenomas and carcinomas. J Gastrointest Surg (2009) 1.04
Molecular characteristics of pancreatic ductal adenocarcinoma. Patholog Res Int (2011) 1.03
Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside. J Gastroenterol (2008) 1.03
Genetic and molecular alterations in pancreatic cancer: implications for personalized medicine. Med Sci Monit (2013) 1.03
Metabolism addiction in pancreatic cancer. Cell Death Dis (2014) 1.02
Molecular analysis of the EGFR-RAS-RAF pathway in pancreatic ductal adenocarcinomas: lack of mutations in the BRAF and EGFR genes. Virchows Arch (2006) 0.99
Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer (2016) 0.98
Expression analysis of candidate breast tumour suppressor genes on chromosome 16q. Breast Cancer Res (2005) 0.96
Molecular pathways in pancreatic carcinogenesis. J Surg Oncol (2012) 0.95
Epigenetics and pancreatic cancer: pathophysiology and novel treatment aspects. World J Gastroenterol (2014) 0.95
ERK kinase phosphorylates and destabilizes the tumor suppressor FBW7 in pancreatic cancer. Cell Res (2015) 0.94
PIK3CA, KRAS, and BRAF mutations in intraductal papillary mucinous neoplasm/carcinoma (IPMN/C) of the pancreas. Langenbecks Arch Surg (2008) 0.94
The Drosophila F-box protein Archipelago controls levels of the Trachealess transcription factor in the embryonic tracheal system. Dev Biol (2007) 0.92
Emerging molecular biology of pancreatic cancer. Gastrointest Cancer Res (2008) 0.87
KRAS(G12D)- and BRAF(V600E)-induced transformation of murine pancreatic epithelial cells requires MEK/ERK-stimulated IGF1R signaling. Mol Cancer Res (2012) 0.86
Green tea epigallocatechin gallate exhibits anticancer effect in human pancreatic carcinoma cells via the inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor. J Biomed Biotechnol (2011) 0.85
Pathology and molecular genetics of pancreatic neoplasms. Cancer J (2012) 0.85
A tumor sorting protocol that enables enrichment of pancreatic adenocarcinoma cells and facilitation of genetic analyses. J Mol Diagn (2009) 0.84
Pathological and molecular evaluation of pancreatic neoplasms. Semin Oncol (2014) 0.83
Notch-dependent expression of the archipelago ubiquitin ligase subunit in the Drosophila eye. Development (2010) 0.83
Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer. Front Oncol (2015) 0.82
The roles of FOXM1 in pancreatic stem cells and carcinogenesis. Mol Cancer (2013) 0.82
FBXW7 Facilitates Nonhomologous End-Joining via K63-Linked Polyubiquitylation of XRCC4. Mol Cell (2016) 0.82
Genetics and pathology of pancreatic cancer. HPB (Oxford) (2006) 0.82
Irrelevance of microsatellite instability in the epidemiology of sporadic pancreatic ductal adenocarcinoma. PLoS One (2012) 0.81
Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Mol Cancer (2012) 0.81
FBXW7 acts as an independent prognostic marker and inhibits tumor growth in human osteosarcoma. Int J Mol Sci (2015) 0.81
Genomic characterization of patient-derived xenograft models established from fine needle aspirate biopsies of a primary pancreatic ductal adenocarcinoma and from patient-matched metastatic sites. Oncotarget (2016) 0.80
Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): Identification of prognostic subtypes. Sci Rep (2017) 0.80
Molecular Biomarkers of Pancreatic Intraepithelial Neoplasia and Their Implications in Early Diagnosis and Therapeutic Intervention of Pancreatic Cancer. Int J Biol Sci (2016) 0.79
The role of oncogenes in gastrointestinal cancer. Gastrointest Cancer Res (2010) 0.78
Fbxw7 Tumor Suppressor: A Vital Regulator Contributes to Human Tumorigenesis. Medicine (Baltimore) (2016) 0.78
Malignant melanoma arising from a perianal fistula and harbouring a BRAF gene mutation: a case report. BMC Cancer (2011) 0.78
Developmental downregulation of Xenopus cyclin E is phosphorylation and nuclear import dependent and is mediated by ubiquitination. Dev Biol (2011) 0.78
Pancreatic Cancer from Molecular Pathways to Treatment Opinion. J Cancer (2016) 0.77
Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies. World J Gastroenterol (2016) 0.77
Intraductal Tubulopapillary Neoplasm of the Pancreas: A Clinicopathologic and Immunohistochemical Analysis of 33 Cases. Am J Surg Pathol (2016) 0.75
FBXW7 expression is associated with prognosis and chemotherapeutic outcome in Chinese patients with gastric adenocarcinoma. BMC Gastroenterol (2017) 0.75
Mitochondriome and cholangiocellular carcinoma. PLoS One (2014) 0.75
RASSF1 tumor suppressor gene in pancreatic ductal adenocarcinoma: correlation of expression, chromosomal status and epigenetic changes. BMC Cancer (2016) 0.75
Expression profiling reveals transcriptional regulation by Fbxw7/mTOR pathway in radiation-induced mouse thymic lymphomas. Oncotarget (2015) 0.75
Fbxw7 Deletion Accelerates Kras(G12D)-Driven Pancreatic Tumorigenesis via Yap Accumulation. Neoplasia (2016) 0.75
MicroRNA-32 promotes cell proliferation, migration and suppresses apoptosis in breast cancer cells by targeting FBXW7. Cancer Cell Int (2017) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Inactivation of the type II TGF-beta receptor in colon cancer cells with microsatellite instability. Science (1995) 13.15
PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 11.11
Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature (2002) 7.46
Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science (2001) 6.29
Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst (2003) 5.64
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature (2001) 5.07
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci U S A (1996) 4.39
Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature (2001) 3.50
hCDC4 gene mutations in endometrial cancer. Cancer Res (2002) 2.36
Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene (1994) 2.04
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res (1995) 1.99
High-throughput tissue microarray analysis of cyclin E gene amplification and overexpression in urinary bladder cancer. Am J Pathol (2000) 1.82
Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. Am J Pathol (2000) 1.69
Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. Cancer Res (2003) 1.58
Genetic profile of gliosarcomas. Am J Pathol (2000) 1.57
Pancreatic adenocarcinomas with DNA replication errors (RER+) are associated with wild-type K-ras and characteristic histopathology. Poor differentiation, a syncytial growth pattern, and pushing borders suggest RER+. Am J Pathol (1998) 1.42
APC/CTNNB1 (beta-catenin) pathway alterations in human prostate cancers. Genes Chromosomes Cancer (2002) 1.35
Alterations in the PITSLRE protein kinase gene complex on chromosome 1p36 in childhood neuroblastoma. Nat Genet (1994) 1.33
Identification and characterization of a 19q12 amplicon in esophageal adenocarcinomas reveals cyclin E as the best candidate gene for this amplicon. Cancer Res (2000) 1.17
Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. Oncogene (1998) 1.06
Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha. Proc Natl Acad Sci U S A (1993) 1.01
Establishment and validation of real-time polymerase chain reaction method for CDH1 promoter methylation. Am J Pathol (2002) 0.99
Molecular cloning and chromosomal localization of the human cyclin C (CCNC) and cyclin E (CCNE) genes: deletion of the CCNC gene in human tumors. Genomics (1996) 0.98
Cyclins in breast cancer: too much of a good thing. Breast Cancer Res (2002) 0.93
Reciprocal expressions of cyclin E and cyclin D1 in hepatocellular carcinoma. Cancer Lett (2001) 0.88
Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science (2008) 36.02
Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science (2009) 18.40
Identification of pancreatic cancer stem cells. Cancer Res (2007) 18.36
Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature (2010) 17.38
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell (2005) 14.21
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med (2015) 13.08
Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science (2011) 11.12
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature (2011) 9.70
International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology (2006) 8.83
Pancreatic cancer. Lancet (2011) 8.54
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature (2012) 8.31
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet (2012) 7.61
Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science (2009) 7.39
International consensus guidelines 2012 for the management of IPMN and MCN of the pancreas. Pancreatology (2012) 7.22
1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. J Gastrointest Surg (2006) 7.18
Pancreatic cancer. Annu Rev Pathol (2008) 6.96
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Delayed gastric emptying (DGE) after pancreatic surgery: a suggested definition by the International Study Group of Pancreatic Surgery (ISGPS). Surgery (2007) 6.62
DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol (2009) 6.43
Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann Surg (2002) 6.24
Pten regulates neuronal arborization and social interaction in mice. Neuron (2006) 6.11
An in vivo platform for translational drug development in pancreatic cancer. Clin Cancer Res (2006) 5.52
Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell (2003) 5.36
Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg (2004) 5.12
Recurrent GNAS mutations define an unexpected pathway for pancreatic cyst development. Sci Transl Med (2011) 5.03
Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol (2010) 4.94
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Postpancreatectomy hemorrhage (PPH): an International Study Group of Pancreatic Surgery (ISGPS) definition. Surgery (2007) 4.72
Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol (2008) 4.70
Altered telomeres in tumors with ATRX and DAXX mutations. Science (2011) 4.60
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol (2006) 4.22
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution. Ann Surg (2007) 3.73
Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Hum Mutat (2011) 3.63
Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol (2011) 3.56
Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways. Proc Natl Acad Sci U S A (2011) 3.51
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet (2013) 3.51
Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science (2011) 3.49
HER-2 gene amplification can be acquired as breast cancer progresses. Proc Natl Acad Sci U S A (2004) 3.43
Prognostic relevance of lymph node ratio following pancreaticoduodenectomy for pancreatic cancer. Surgery (2007) 3.42
Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. Am J Pathol (2003) 3.40
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med (2004) 3.39
Gallbladder cancer: the role of laparoscopy and radical resection. Ann Surg (2007) 3.38
Assessment of complications after pancreatic surgery: A novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg (2006) 3.35
Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res (2004) 3.31
ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov (2011) 3.27
The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature (2012) 3.23
Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Res (2003) 3.23
Evaluating the impact of a single-day multidisciplinary clinic on the management of pancreatic cancer. Ann Surg Oncol (2008) 3.14
Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol (2004) 3.10
Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. Am J Surg Pathol (2006) 3.01
A compendium of potential biomarkers of pancreatic cancer. PLoS Med (2009) 3.00
Recent progress in pancreatic cancer. CA Cancer J Clin (2013) 2.88
Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol (2007) 2.87
Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain. Cancer Cell (2011) 2.87
Focus on pancreas cancer. Cancer Cell (2002) 2.82
Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch (2005) 2.76
Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res (2004) 2.75
Presence of somatic mutations in most early-stage pancreatic intraepithelial neoplasia. Gastroenterology (2012) 2.74
MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res (2013) 2.71
LigAmp for sensitive detection of single-nucleotide differences. Nat Methods (2004) 2.70
Multiple-criterion evaluation of reported mutations: a proposed scoring system for the intragenic somatic mutation literature. Cancer Biol Ther (2006) 2.70
Frequent detection of pancreatic lesions in asymptomatic high-risk individuals. Gastroenterology (2012) 2.69
mTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci U S A (2003) 2.68
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Biomarker discovery from pancreatic cancer secretome using a differential proteomic approach. Mol Cell Proteomics (2005) 2.66
Gene expression profiles in pancreatic intraepithelial neoplasia reflect the effects of Hedgehog signaling on pancreatic ductal epithelial cells. Cancer Res (2005) 2.64
Multicomponent analysis of the pancreatic adenocarcinoma progression model using a pancreatic intraepithelial neoplasia tissue microarray. Mod Pathol (2003) 2.63
Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg (2005) 2.58